Merck & Company (MRK) has received a Buy rating from BMO Capital, with analyst Evan Seigerman setting a price target of $170.00. Seigerman, who focuses on the Healthcare sector, has a track record of a 9.6% average return and a 54.82% success rate on recommended stocks, according to TipRanks.
In addition to BMO Capital’s rating, Merck also earned a Buy from Morgan Stanley’s Terence Flynn in a report issued yesterday. However, Cantor Fitzgerald maintained a Hold rating on Merck today, reflecting a more cautious stance.
Merck’s latest earnings report for the quarter ending June 30 showed quarterly revenue of $16.61 billion and a GAAP net loss of $1.34 billion. This contrasts with the same period last year, when the company reported revenue of $15.8 billion and a net profit of $4.43 billion.
The corporate insider sentiment for Merck is currently negative, with 53 insiders having sold shares in the past quarter. Most recently, Jennifer Zachary, the EVP & GC of MRK, sold 80,315 shares in August 2026 for a total of $10,718,036.75.